On Monday, Microsoft Corporation (NASDAQ:MSFT) CEO Satya Nadella unveiled an AI system that outperforms human doctors in diagnosing complex medical cases, signaling a major leap toward “medical superintelligence.”
What Happened: Microsoft detailed two major advances: SDBench and MAI-DxO in a blog post titled, "The Path to Medical Superintelligence."
SDBench: This tool uses 304 case studies from the New England Journal of Medicine (NEJM) and turns them into interactive diagnostic simulations. The AI must think critically, ask questions, order tests and weigh the costs—much like a real-life doctor.
MAI-DxO: This is a model-agnostic orchestrator that simulates a panel of virtual physicians. It achieved 85.5% diagnostic accuracy, which is four times higher than experienced human doctors, while also reducing diagnostic costs.
"Excited to share two advances that bring us closer to real-world impact in healthcare AI," Nadella posted on X, formerly Twitter. "Together, these advances offer a blueprint for how AI can help deliver precision and efficiency in healthcare."
Microsoft admitted that this technology isn't ready to be used in real medical settings yet. The "orchestrator" still needs more testing, especially to see how well it handles everyday symptoms and routine cases, the company said.
Mustafa Suleyman, head of Microsoft AI, told The Guardian: "It's pretty clear that we are on a path to these systems getting almost error-free in the next 5-10 years. It will be a massive weight off the shoulders of all health systems around the world."
Why It's Important: In the third week of June 2025, investors poured significant capital into AI startups and acquisitions, signaling strong confidence in artificial intelligence despite wider market uncertainty.
Major funding rounds included NYC's Tennr, which raised $101 million to advance AI-driven clinical intelligence and RevelAi Health, which secured $3.1 million for predictive medical tools aimed at better patient outcomes and lower costs.
Data analytics also saw big wins: PreciseDx landed $11 million to expand its AI-powered diagnostic imaging, while Typedef attracted $5.5 million to make complex analytics more accessible for businesses.
Price Action: Microsoft (MSFT) shares edged up 0.30% during Monday's regular trading session but slipped slightly by 0.012% in after-hours trading, according to Benzinga Pro data. The stock has climbed 18.83% so far this year and is up 8.81% over the past 12 months.
Benzinga's Edge Stock Rankings show that MSFT maintains a solid upward price trend in the short, medium, and long term. However, while its momentum remains strong, its value ranking is comparatively weaker. More detailed performance metrics are available here.
Photo Courtesy: katuSka on Shutterstock.com
Read Next:
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
